Iradimed (NASDAQ:IRMD) Issues Q1 2025 Earnings Guidance

Iradimed (NASDAQ:IRMD - Get Free Report) issued an update on its first quarter 2025 earnings guidance on Thursday morning. The company provided EPS guidance of 0.390-0.430 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $19.2 million-$19.4 million, compared to the consensus revenue estimate of $19.1 million. Iradimed also updated its FY 2025 guidance to 1.710-1.810 EPS.

Iradimed Price Performance

Shares of IRMD traded down $0.17 on Monday, reaching $55.23. 51,661 shares of the stock traded hands, compared to its average volume of 36,478. The stock's 50-day moving average price is $57.20 and its 200-day moving average price is $52.18. The firm has a market cap of $699.76 million, a price-to-earnings ratio of 37.83 and a beta of 0.82. Iradimed has a 12 month low of $40.18 and a 12 month high of $63.29.

Iradimed (NASDAQ:IRMD - Get Free Report) last announced its quarterly earnings data on Thursday, February 13th. The medical equipment provider reported $0.40 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.05). Iradimed had a net margin of 26.12% and a return on equity of 23.99%. The business had revenue of $19.39 million during the quarter, compared to analyst estimates of $19.09 million. As a group, equities research analysts forecast that Iradimed will post 1.52 earnings per share for the current fiscal year.

Iradimed Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, March 5th. Shareholders of record on Monday, February 24th will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.23%. This is an increase from Iradimed's previous quarterly dividend of $0.15. The ex-dividend date is Monday, February 24th. Iradimed's payout ratio is presently 41.10%.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. StockNews.com lowered Iradimed from a "strong-buy" rating to a "buy" rating in a research note on Thursday. Roth Mkm restated a "buy" rating and issued a $72.00 target price (up previously from $60.00) on shares of Iradimed in a research note on Friday.

Insider Transactions at Iradimed

In other Iradimed news, CFO John Glenn sold 2,500 shares of the stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $54.18, for a total value of $135,450.00. Following the transaction, the chief financial officer now directly owns 4,383 shares in the company, valued at approximately $237,470.94. This trade represents a 36.32 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 37.10% of the company's stock.

About Iradimed

IRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL.